First Tracks Biotherapeutics Q3 2026 net loss narrows 25% to $31.36 million
TRAX•First Tracks Biotherapeutics’ third-quarter net loss narrowed 25% year over year to $31.36 million, while research and development expenses fell 28% to $23.85 million. The company also reported an October private placement that raised $200 million in gross proceeds and positive Phase 1b results for ANB033 in celiac disease.
1. Quarterly results
First Tracks Biotherapeutics’ third-quarter 2026 net loss narrowed 25% year over year to $31.36 million. Research and development expenses fell 28% to $23.85 million, primarily due to lower development costs for rosnilimab and ANB032.
2. Pipeline and financing
An October private placement raised $200 million in gross proceeds. ANB033 demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms in a Phase 1b celiac disease cohort. A late-stage celiac disease trial is planned for 2027, and mucosal-healing cohort results are expected in the first quarter of 2027.
